Search Results - Gideon Bollag
- Showing 1 - 20 results of 48
- Go to Next Page
-
1
-
2
Discovery of a novel Raf kinase inhibitor. by John F. Lyons, S M Wilhelm, Barbara Hibner, Gideon Bollag
Published 2001Revisão -
3
-
4
-
5
-
6
-
7
-
8
-
9
Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in<i>BRAF</i>Mutant Thyroid Carcinoma Cells by Paolo Salerno, Valentina De Falco, Anna Tamburrino, Tito Claudio Nappi, Giancarlo Vecchio, Rebecca E. Schweppe, Gideon Bollag, Massimo Santoro, Giuliana Salvatore
Published 2009Artigo -
10
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma by Peter G. Smith, Fengfei Wang, Kathryn Wilkinson, Kerry J. Savage, Ulf Klein, Donna Neuberg, Gideon Bollag, Margaret A. Shipp, Ricardo C.T. Aguiar
Published 2004Artigo -
11
-
12
-
13
-
14
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer by Ross A. Okimoto, Luping Lin, Victor Olivas, Elton Chan, Evan Markegard, Andrey Rymar, Dana S. Neel, Xiaohong Chen, Golzar Hemmati, Gideon Bollag, Trever G. Bivona
Published 2016Artigo -
15
Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer by Carmelo Nucera, Matthew A. Nehs, Sushruta S. Nagarkatti, Peter M. Sadow, Michal Mekel, Andrew H. Fischer, Paul Lin, Gideon Bollag, Jack Lawler, Richard A. Hodin, Sareh Parangi
Published 2011Artigo -
16
PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas by John Tayu Lee, Ling Li, Patricia Brafford, Marcia van den Eijnden, Molly B. Halloran, Katrin Sproesser, Nikolas K. Haass, Keiran S.M. Smalley, James Tsai, Gideon Bollag, Meenhard Herlyn
Published 2010Artigo -
17
Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer by Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su
Published 2011Artigo -
18
Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma by William D. Tap, Ke-Wei Gong, Judy Daring, Yiou Tseng, Charles Ginther, Giovanni M. Pauletti, John A. Glaspy, Richard Essner, Gideon Bollag, Peter Hirth, Chao Zhang, Dennis J. Slamon
Published 2010Artigo -
19
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model by Daniele Perna, Florian A. Karreth, Alistair G. Rust, Pedro A. Pérez–Mancera, Mamunur Rashid, Francesco Iorio, Constantine Alifrangis, Mark J. Arends, Marcus Bosenberg, Gideon Bollag, David A. Tuveson, David J. Adams
Published 2015Artigo -
20
Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition by Carlos E. Prada, Edwin Jousma, Tilat A. Rizvi, Jianqiang Wu, R. Scott Dunn, Debra A. Mayes, José A. Cancelas, Eva Dombi, Mi‐Ok Kim, Brian L. West, Gideon Bollag, Nancy Ratner
Published 2012Artigo
Search Tools:
Related Subjects
Biology
Cancer research
Gene
Medicine
Genetics
Cancer
Kinase
Internal medicine
Biochemistry
Cell biology
Mutation
Signal transduction
MAPK/ERK pathway
Melanoma
KRAS
Mutant
V600E
Metastatic melanoma
Vemurafenib
Chemistry
Cell cycle
Protein kinase A
Colorectal cancer
Oncogene
Pathology
Receptor
Endocrinology
Immunology
Oncology
PI3K/AKT/mTOR pathway